DFP-11207

synthetic antimetabolite with lower toxicity than 5-FU

Also Known As:

5-chloro-2-(3-(3-(ethoxymethyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydopy-rimidine-1-carbonyl)benzoyloxy)pyridine-4-yl-2,6-bis (propionyloxy)isonicotinate

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - Fluorinated Hydrocarbons: 4
      - DFP-11207: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - DFP-11207: 2

Experts

1.	Iizuka, Kenzo: 2 articles (12/2020 - 01/2017)
2.	Zhang, Chun: 2 articles (12/2020 - 01/2017)
3.	Ajani, Jaffer A: 1 article (12/2020)
4.	Anderson, Barry: 1 article (12/2020)
5.	Eng, Cathy: 1 article (12/2020)
6.	Fogelman, David: 1 article (12/2020)
7.	Javle, Milind: 1 article (12/2020)
8.	Smith, Jackie: 1 article (12/2020)
9.	Eshima, Kiyoshi: 1 article (01/2017)
10.	Fukushima, Masakazu: 1 article (01/2017)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2020 - "Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors." 01/01/2017 - "The antitumor activity of DFP-11207 was evaluated in human tumor xenografts in nude rats and found that DFP-11207 showed an antitumor activity in a dose-dependent fashion and its efficacy is equivalent to reference 5-FU drugs. " 01/01/2017 - "Especially, DFP-11207 inhibited the intracellular phosphorylation of 5-FU in tumor cells in a dose-dependent manner whereas CTA alone did not protect intracellular 5-FU phosphorylation. " 01/01/2017 - "In vitro studies of DFP-11207 indicated that it strongly inhibited the degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD) in homogenates of the rat liver, and also inhibited the phosphorylation of 5-FU by orotate phosphoribosyltransferase (OPRT) in tumor tissues in a similar magnitude of potency by CDHP and CTA, respectively. "
2.	Gallbladder Neoplasms (Gallbladder Cancer) 12/01/2020 - "In this Phase I study (NCT02171221), DFP-11207 was administered orally daily, in doses escalating from 40 mg/m2/day to 400 mg/m2/day in patients with esophageal, colorectal, gastric, pancreatic or gallbladder cancer (n = 23). "
3.	Thrombocytopenia (Thrombopenia) 01/01/2017 - "In striking contrast, DFP-11207 manifested no or less 5-FU-related toxicities, such as a decrease in body weights, GI injury, and myelosuppression, especially thrombocytopenia. "
4.	Body Weight (Weight, Body) 01/01/2017 - "In striking contrast, DFP-11207 manifested no or less 5-FU-related toxicities, such as a decrease in body weights, GI injury, and myelosuppression, especially thrombocytopenia. "

Related Drugs and Biologics

1.	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
2.	Orotate Phosphoribosyltransferase
3.	Fluorouracil (Carac)